ArticleJournal of cancer research and clinical oncology2003
Impact of c-Met expression on angiogenesis in soft tissue sarcomas: correlation to microvessel-density.
Article in Journal of cancer research and clinical oncology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- Article
- Article
- A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).Pediatric blood & cancer · 2017Article
- New drugs and combinations for the treatment of soft-tissue sarcoma: a review.Cancer management and research · 2012Article
- Expression of hepatocyte growth factor and its receptor c-Met in human pituitary adenomas.Neuro-oncology · 2010Article
- Acquisition of biologically relevant gene expression data by Affymetrix microarray analysis of archival formalin-fixed paraffin-embedded tumours.British journal of cancer · 2008Article
- Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype.The Journal of clinical investigation · 2006Article
- Current status and perspective of antiangiogenic therapy for cancer: urinary cancer.International journal of clinical oncology · 2006Review
- Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis.Neuro-oncology · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PURPOSE AND
methodsThe c-Met protein is significant for oncogenesis and angiogenesis within the c-Met/HGF/SF-mediator system. The aim of this study was the analysis of c-Met immunoexpression/-synthesis and microvessel density as parameters for angiogenesis and prognosis in 115 soft tissue sarcomas.
resultsC-Met could be detected by immunohistochemistry in 87% of sarcomas. In all, 60.9% of cases exhibited absent or faint expression of c-Met protein, and 39.1% high expression of c-Met protein with a correlation between tumor grading and c-Met immunoexpression. Using in situ hybridization with detection of c-met-mRNA-transcripts, c-Met protein synthesis within tumor cells could be demonstrated. A statistically significant correlation between c-Met immunoexpression and tumor microvessel density was found. No prognostic value of c-Met expression and microvessel density could be detected in 56 patients with clinical follow-up ( P=0.8506 and P=0.9329 for disease-free survival).
conclusionsThe results underline a role of c-Met as an oncoprotein in soft tissue sarcomas with correlation between immunoexpression and grading. The statistically significant correlation between c-Met expression and microvessel density (as a parameter of tumor angiogenesis) suggests an angiogenic function of the c-Met/HGF/SF mediator system in malignant mesenchymal tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.